Mark A Kay

List of Publications by Year
in descending order

241 papers	36,399 citations	3531 90 h-index	3106 187 g-index
251 all docs	251 docs citations	251 times ranked	27790 citing authors

#	Article	IF	Citations
1	Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice. Frontiers in Genome Editing, 2022, 4, 785698.	5.2	8
2	Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice. Nature Biotechnology, 2022, 40, 1285-1294.	17.5	8
3	Evaluating the state of the science for adeno-associated virus integration: An integrated perspective. Molecular Therapy, 2022, 30, 2646-2663.	8.2	65
4	Promoterless, Nucleaseâ€Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia. Hepatology, 2021, 73, 2223-2237.	7.3	36
5	Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex. Molecular Therapy, 2021, 29, 1016-1027.	8.2	7
6	Evaluating the Genomic Parameters Governing rAAV-Mediated Homologous Recombination. Molecular Therapy, 2021, 29, 1028-1046.	8.2	6
7	The Role of tRNA Derived Small RNAs in Gene Regulation in Normal Tissues and Cancer. FASEB Journal, 2021, 35, .	0.5	0
8	RNA structure probing reveals the structural basis of Dicer binding and cleavage. Nature Communications, 2021, 12, 3397.	12.8	36
9	The 3â€™tsRNAs are aminoacylated: Implications for their biogenesis. PLoS Genetics, 2021, 17, e1009675.	3.5	10
10	Selective Microvascular Tissue Transfection Using Minicircle DNA for Systemic Delivery of Human Coagulation Factor IX in a Rat Model Using a Therapeutic Flap. Plastic and Reconstructive Surgery, 2021, Publish Ahead of Print, .	1.4	1
11	Transfer RNA-Derived Small RNAs: Another Layer of Gene Regulation and Novel Targets for Disease Therapeutics. Molecular Therapy, 2020, 28, 2340-2357.	8.2	57
12	Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals. Nature Methods, 2020, 17, 852-860.	19.0	123
13	Evolution of a Human-Specific Tandem Repeat Associated with ALS. American Journal of Human Genetics, 2020, 107, 445-460.	6.2	39
14	AAV vectors engineered to target insulin receptor greatly enhance intramuscular gene delivery. Molecular Therapy - Methods and Clinical Development, 2020, 19, 496-506.	4.1	8
15	Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing. Human Gene Therapy, 2020, 31, 553-564.	2.7	19
16	The Role of tRNA Derived Small RNAs in Gene Regulation in Normal Tissues and Cancer. FASEB Journal, 2020, 34, 1-1.	0.5	0
17	Abstract LB-343: A Leu(CAG)-tRNA derived small RNA regulates ribosomal protein S28 after translation initiation in both human and mouse liver cancers. , 2020, , .		0
18	Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation. Circulation, 2019, 140, 765-778.	1.6	26

#	Article	IF	Citations
19	An orange calcium-modulated bioluminescent indicator for non-invasive activity imaging. Nature Chemical Biology, 2019, 15, 433-436.	8.0	37
20	A tRNA-Derived Small RNA Regulates Ribosomal Protein S28 Protein Levels after Translation Initiation in Humans and Mice. Cell Reports, 2019, 29, 3816-3824.e4.	6.4	52
21	Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. JCI Insight, 2019, 4, .	5.0	28
22	Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight, 2019, 4, .	5.0	64
23	Bioengineered AAV Capsids with Combined High Human Liver Transduction InÂVivo and Unique Humoral Seroreactivity. Molecular Therapy, 2018, 26, 289-303.	8.2	130
24	miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression. Nature Communications, 2018, 9, 5321.	12.8	48
25	Bioengineered Viral Platform for Intramuscular Passive Vaccine Delivery to Human Skeletal Muscle. Molecular Therapy - Methods and Clinical Development, 2018, 10, 144-155.	4.1	21
26	Abstract LB-390: A transfer RNA derived small RNA affects translation in rapidly dividing cells and a target for hepatocellular carcinoma. , 2018, , .		0
27	Abstract IA03: Functional lung cancer genomics through in vivo genome editing. , 2018, , .		0
28	Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond. Human Gene Therapy, 2017, 28, 361-372.	2.7	40
29	A 5â€² Noncoding Exon Containing Engineered Intron Enhances Transgene Expression from Recombinant AAV Vectors in vivo. Human Gene Therapy, 2017, 28, 125-134.	2.7	21
30	Sequence-Modified Antibiotic Resistance Genes Provide Sustained Plasmid-Mediated Transgene Expression in Mammals. Molecular Therapy, 2017, 25, 1187-1198.	8.2	10
31	Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of Î±-1 Antitrypsin Deficiency. Molecular Therapy, 2017, 25, 2477-2489.	8.2	62
32	Promoterless gene targeting without nucleases rescues lethality of a Criglerâ€Najjar syndrome mouse model. EMBO Molecular Medicine, 2017, 9, 1346-1355.	6.9	46
33	Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nature Communications, 2017, 8, 2053.	12.8	78
34	A transfer-RNA-derived small RNA regulates ribosome biogenesis. Nature, 2017, 552, 57-62.	27.8	366
35	Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid Î±-glucosidase. Science Translational Medicine, 2017, 9, .	12.4	103
36	Regulated complex assembly safeguards the fidelity ofSleeping Beautytransposition. Nucleic Acids Research, 2017, 45, 311-326.	14.5	31

#	Article	IF	Citations
37	129. Does Transcription Influence AAV-Mediated Homologous Recombination?. Molecular Therapy, 2016, 24, S53.	8.2	0
38	257. Selection of Next Generation AAV Gene Therapy Vectors for Specific and Precise Gene Delivery. Molecular Therapy, 2016, 24, S101.	8.2	0
39	737. RNAi Induced Hepatotoxicity Results from a Functional Depletion of the First Synthesized Isoform of miR-122. Molecular Therapy, 2016, 24, S290-S291.	8.2	0
40	48. Treatment of Methylmalonic Acidemia by Promoterless Gene-Targeting Using Adeno-Associated Viral (AAV) Mediated Homologous Recombination. Molecular Therapy, 2016, 24, S21-S22.	8.2	0
41	253. Expanded Packaging Capacity of AAV by Lumenal Charge Alteration. Molecular Therapy, 2016, 24, S99-S100.	8.2	2
42	289. Sequence Modified Antibiotic Resistance Genes Provide Sustained Plasmid Mediated Transgene Expression in Mammals. Molecular Therapy, 2016, 24, S116.	8.2	0
43	539. Screening for Recombinant Adeno-Associated Viral Vectors That Selectively Transduce Hepatitis B Virus Infected Cells. Molecular Therapy, 2016, 24, S215.	8.2	0
44	722. AAV Capsid Evolution for Enhanced Antibody Delivery to Human Skeletal Muscle for Use in Next-Generation HIV Vaccines and Muscle Gene Therapies. Molecular Therapy, 2016, 24, S284-S285.	8.2	0
45	A Tribute to George Stamatoyannopoulos. Human Gene Therapy, 2016, 27, 280-286.	2.7	0
46	RNA interferenceâ€“induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice. Nature Medicine, 2016, 22, 557-562.	30.7	32
47	Increased precursor microRNA-21 following status epilepticus can compete with mature microRNA-21 to alter translation. Experimental Neurology, 2016, 286, 137-146.	4.1	11
48	Dieter C. Gruenert, PhD (1949â€“2016). Nucleic Acid Therapeutics, 2016, 26, 266-267.	3.6	0
49	A universal system to select gene-modified hepatocytes in vivo. Science Translational Medicine, 2016, 8, 342ra79.	12.4	38
50	A bright cyan-excitable orange fluorescent protein facilitates dual-emission microscopy and enhances bioluminescence imaging in vivo. Nature Biotechnology, 2016, 34, 760-767.	17.5	221
51	94. AAV Integration Site Determination Using Illumina Mate Pair Sequencing. Molecular Therapy, 2015, 23, S39-S40.	8.2	0
52	303. AAV Capsid Evolution for Enhanced Antibody Delivery To Human Muscle for Use in Next-Generation HIV Vaccines. Molecular Therapy, 2015, 23, S122-S123.	8.2	0
53	305. A Screening Strategy for Selecting Recombinant Adeno-Associated Viral Vectors That Selectively Transduce Viral Infected Cells. Molecular Therapy, 2015, 23, S123.	8.2	0
54	578. microRNA Inhibition Through Gapmer Activated RNase H-Mediated Degradation. Molecular Therapy, 2015, 23, S230.	8.2	0

#	Article	IF	Citations
55	683. In Vivo Expansion of Hepatocytes with Targeted rAAV Integration Results in a >100-Fold Increase of Transgene Expression. Molecular Therapy, 2015, 23, S272.	8.2	0
56	688. AAV8-Mediated Liver Gene Targeting Without Nucleases Rescues Lethality in a Mouse Model of the Crigler-Najjar Syndrome. Molecular Therapy, 2015, 23, S274.	8.2	0
57	Selecting the Best AAV Capsid for Human Studies. Molecular Therapy, 2015, 23, 1800-1801.	8.2	11
58	Novel codon-optimized mini-intronic plasmid for efficient, inexpensive and xeno-free induction of pluripotency. Scientific Reports, 2015, 5, 8081.	3.3	51
59	Drugging RNAi. Science, 2015, 347, 1069-1070.	12.6	74
60	Translational Data from Adeno-Associated Virus-Mediated Gene Therapy of Hemophilia B in Dogs. Human Gene Therapy Clinical Development, 2015, 26, 5-14.	3.1	29
61	Viral Vectors Take On HIV Infection. New England Journal of Medicine, 2015, 373, 770-772.	27.0	2
62	Recombinant AAV as a Platform for Translating the Therapeutic Potential of RNA Interference. Molecular Therapy, 2014, 22, 692-701.	8.2	111
63	Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs. Human Gene Therapy Clinical Development, 2014, , 150127063140004.	3.1	2
64	Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B. New England Journal of Medicine, 2014, 371, 1994-2004.	27.0	1,063
65	Characterization of Vector-Based Delivery ofNeurogenin-3in Murine Diabetes. Human Gene Therapy, 2014, 25, 651-661.	2.7	5
66	Weak base pairing in both seed and 3â€² regions reduces RNAi off-targets and enhances si/shRNA designs. Nucleic Acids Research, 2014, 42, 12169-12176.	14.5	27
67	Human COL7A1 -corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Science Translational Medicine, 2014, 6, 264ra163.	12.4	194
68	Somatic Correction of Junctional Epidermolysis Bullosa by a Highly Recombinogenic AAV Variant. Molecular Therapy, 2014, 22, 725-733.	8.2	60
69	Engineering Cellular Resistance to HIV. New England Journal of Medicine, 2014, 370, 968-969.	27.0	8
70	Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014, 506, 382-386.	27.8	376
71	Regulation of microRNA-mediated gene silencing by microRNA precursors. Nature Structural and Molecular Biology, 2014, 21, 825-832.	8.2	23
72	Organ Size Control Is Dominant over Rb Family Inactivation to Restrict Proliferation InÂVivo. Cell Reports, 2014, 8, 371-381.	6.4	30

#	Article	IF	Citations
73	Genome Editing of Isogenic Human Induced Pluripotent Stem Cells Recapitulates Long QT Phenotype for Drug Testing. Journal of the American College of Cardiology, 2014, 64, 451-459.	2.8	149
74	Minicircle DNA Vectors Achieve Sustained Expression Reflected by Active Chromatin and Transcriptional Level. Molecular Therapy, 2013, 21, 131-138.	8.2	103
75	A Mini-intronic Plasmid (MIP): A Novel Robust Transgene Expression Vector In Vivo and In Vitro. Molecular Therapy, 2013, 21, 954-963.	8.2	51
76	The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. Nucleic Acids Research, 2013, 41, 3688-3698.	14.5	12
77	Cellular Immune Responses To Vector In a Gene Therapy Trial For Hemophilia B Using An AAV8 Self-Complementary Factor IX Vector. Blood, 2013, 122, 717-717.	1.4	0
78	AAV Vectors Containing rDNA Homology Display Increased Chromosomal Integration and Transgene Persistence. Molecular Therapy, 2012, 20, 1902-1911.	8.2	36
79	Ribosomal DNA Integrating rAAV-rDNA Vectors Allow for Stable Transgene Expression. Molecular Therapy, 2012, 20, 1912-1923.	8.2	27
80	Genome Editing of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells With Zinc Finger Nucleases for Cellular Imaging. Circulation Research, 2012, 111, 1494-1503.	4.5	99
81	rAAV-Mediated Tumorigenesis: Still Unresolved After an AAV Assault. Molecular Therapy, 2012, 20, 2014-2017.	8.2	33
82	Expression determinants of mammalian argonaute proteins in mediating gene silencing. Nucleic Acids Research, 2012, 40, 3704-3713.	14.5	35
83	The Loop Position of shRNAs and Pre-miRNAs Is Critical for the Accuracy of Dicer Processing InÂVivo. Cell, 2012, 151, 900-911.	28.9	266
84	The Extragenic Spacer Length Between the 5â€² and 3â€² Ends of the Transgene Expression Cassette Affects Transgene Silencing From Plasmid-based Vectors. Molecular Therapy, 2012, 20, 2111-2119.	8.2	55
85	Stable Factor IX Activity Following AAV-Mediated Gene Transfer in Patients with Severe Hemophilia B. Blood, 2012, 120, 752-752.	1.4	2
86	Minicircle DNA-based Gene Therapy Coupled With Immune Modulation Permits Long-term Expression of Î±-L-Iduronidase in Mice With Mucopolysaccharidosis Type I. Molecular Therapy, 2011, 19, 450-460.	8.2	86
87	Adenovirus-Associated Virus Vectorâ€"Mediated Gene Transfer in Hemophilia B. New England Journal of Medicine, 2011, 365, 2357-2365.	27.0	1,606
88	Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. Journal of Clinical Investigation, 2011, 121, 4850-4860.	8.2	376
89	State-of-the-art gene-based therapies: the road ahead. Nature Reviews Genetics, 2011, 12, 316-328.	16.3	587
90	Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9208-9213.	7.1	71

#	Article	IF	Citations
91	Adeno-Associated Viral Vector Mediated Gene Transfer for Hemophilia B. Blood, 2011, 118, 5-5.	1.4	4
92	Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology, 2010, 51, 1200-1208.	7.3	121
93	An in vitro-identified high-affinity nucleosome-positioning signal is capable of transiently positioning a nucleosome in vivo. Epigenetics and Chromatin, 2010, 3, 13.	3.9	20
94	How do miRNAs mediate translational repression?. Silence: A Journal of RNA Regulation, 2010, 1, 11.	8.1	140
95	A robust system for production of minicircle DNA vectors. Nature Biotechnology, 2010, 28, 1287-1289.	17.5	288
96	A nonviral minicircle vector for deriving human iPS cells. Nature Methods, 2010, 7, 197-199.	19.0	658
97	Human tRNA-derived small RNAs in the global regulation of RNA silencing. Rna, 2010, 16, 673-695.	3.5	583
98	FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E384-E393.	3.5	161
99	Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice. Molecular Therapy, 2010, 18, 161-170.	8.2	39
100	Hyperactive Sleeping Beauty Transposase Enables Persistent Phenotypic Correction in Mice and a Canine Model for Hemophilia B. Molecular Therapy, 2010, 18, 1896-1906.	8.2	75
101	Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. Journal of Clinical Investigation, 2010, 120, 3106-3119.	8.2	161
102	Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B. Blood, 2010, 116, 248-248.	1.4	19
103	Combined proteomicâ€"RNAi screen for host factors involved in human hepatitis delta virus replication. Rna, 2009, 15, 1971-1979.	3.5	43
104	A rapid protocol for construction and production of high-capacity adenoviral vectors. Nature Protocols, 2009, 4, 547-564.	12.0	66
105	Biological basis for restriction of microRNA targets to the 3â€² untranslated region in mammalian mRNAs. Nature Structural and Molecular Biology, 2009, 16, 144-150.	8.2	383
106	Novel Minicircle Vector for Gene Therapy in Murine Myocardial Infarction. Circulation, 2009, 120, S230-7.	1.6	91
107	Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells. Hepatology, 2008, 47, 706-718.	7.3	10
108	Capped small RNAs and MOV10 in human hepatitis delta virus replication. Nature Structural and Molecular Biology, 2008, 15, 714-721.	8.2	72

#	Article	IF	Citations
109	In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses. Journal of Virology, 2008, 82, 5887-5911.	3.4	546
110	Radioprotection In Vitro and In Vivo by Minicircle Plasmid Carrying the Human Manganese Superoxide Dismutase Transgene. Human Gene Therapy, 2008, 19, 820-826.	2.7	60
111	Silencing of Hepatic Fatty Acid Transporter Protein 5 in Vivo Reverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia. Journal of Biological Chemistry, 2008, 283, 22186-22192.	3.4	133
112	Silencing of Episomal Transgene Expression in Liver by Plasmid Bacterial Backbone DNA Is Independent of CpG Methylation. Molecular Therapy, 2008, 16, 548-556.	8.2	141
113	The Host Response to Adenovirus, Helper-dependent Adenovirus, and Adeno-associated Virus in Mouse Liver. Molecular Therapy, 2008, 16, 931-941.	8.2	93
114	Expression of shRNA From a Tissue-specific pol II Promoter Is an Effective and Safe RNAi Therapeutic. Molecular Therapy, 2008, 16, 1630-1636.	8.2	183
115	Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14771-14776.	7.1	193
116	Somatic Integration From an Adenoviral Hybrid Vector into a Hot Spot in Mouse Liver Results in Persistent Transgene Expression Levels In Vivo. Molecular Therapy, 2007, 15, 146-156.	8.2	41
117	Histone Modifications are Associated with the Persistence or Silencing of Vector-mediated Transgene Expression In Vivo. Molecular Therapy, 2007, 15, 1348-1355.	8.2	123
118	Correction of DNA Protein Kinase Deficiency by Spliceosome-mediated RNA Trans-splicing and Sleeping Beauty Transposon Delivery. Molecular Therapy, 2007, 15, 1273-1279.	8.2	24
119	Adenovirus Transduction is Required for the Correction of Diabetes Using Pdx-1 or Neurogenin-3 in the Liver. Molecular Therapy, 2007, 15, 255-263.	8.2	111
120	Site-directed transposon integration in human cells. Nucleic Acids Research, 2007, 35, e50-e50.	14.5	129
121	Rapid and Stable Knockdown of an Endogenous Gene in Retinal Pigment Epithelium. Human Gene Therapy, 2007, 18, 871-880.	2.7	22
122	Cis-Acting Gene Regulatory Activities in the Terminal Regions of Sleeping Beauty DNA Transposon-Based Vectors. Human Gene Therapy, 2007, 18, 1193-1204.	2.7	39
123	The Role of DNA-PKcs and Artemis in Opening Viral DNA Hairpin Termini in Various Tissues in Mice. Journal of Virology, 2007, 81, 11304-11321.	3.4	61
124	DNA Palindromes with a Modest Arm Length of â‰³20 Base Pairs Are a Significant Target for Recombinant Adeno-Associated Virus Vector Integration in the Liver, Muscles, and Heart in Mice. Journal of Virology, 2007, 81, 11290-11303.	3.4	48
125	microRNAs outwit immune limitations in gene therapy. Blood, 2007, 110, 4136-4137.	1.4	0
126	RNAi and Gene Therapy: A Mutual Attraction. Hematology American Society of Hematology Education Program, 2007, 2007, 473-481.	2.5	75

#	Article	IF	Citations
127	AAV vectors and tumorigenicity. Nature Biotechnology, 2007, 25, 1111-1113.	17.5	38
128	Robust expansion of human hepatocytes in Fahâˆ’/âˆ’/Rag2âˆ’/âˆ’/Il2rgâˆ’/âˆ’ mice. Nature Biotechnology, 2007, 25, 903-910.	17.5	729
129	Sarcoma Derived from Cultured Mesenchymal Stem Cells. Stem Cells, 2007, 25, 371-379.	3.2	601
130	Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?. Journal of Clinical Investigation, 2007, 117, 3633-3641.	8.2	132
131	Minicircle Plasmid Containing the Human Manganese Superoxide Dismutase (MnSOD) Transgene Confers Radioprotection to Hematopoietic Progenitor Cell Line 32Dcl3.. Blood, 2007, 110, 5138-5138.	1.4	0
132	374. Hepatitis Delta Virus-Mediated Amplification of Therapeutic RNAi. Molecular Therapy, 2006, 13, S142.	8.2	0
133	Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood, 2006, 107, 4182-4188.	1.4	75
134	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	30.7	1,865
135	Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 2006, 441, 537-541.	27.8	1,518
136	Liver Transduction with Recombinant Adeno-Associated Virus Is Primarily Restricted by Capsid Serotype Not Vector Genotype. Journal of Virology, 2006, 80, 426-439.	3.4	104
137	The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9. Journal of Virology, 2006, 80, 9831-9836.	3.4	356
138	516. Development of a Minicircle Vector Free of Plasmid Bacterial DNA Sequences and Capable of Ã¸C31-Mediated Site-Specific Integration. Molecular Therapy, 2006, 13, S198-S199.	8.2	0
139	796. Pol II-Driven shRNA as an Effective Hepatitis B Virus Therapeutic. Molecular Therapy, 2006, 13, S308-S309.	8.2	0
140	9. Biology of rAAV8 in Mouse Liver Following Vector Administration at Birth. Molecular Therapy, 2006, 13, S4.	8.2	0
141	114. Revisiting rAAV Vector Integration in scid Mice: DNA-PKcs Deficiency Does Not Substantially Increase Integration Frequency in Hepatic and Non-Hepatic Tissues In Vivo. Molecular Therapy, 2006, 13, S47.	8.2	0
142	1099. RNAi-Based Therapy for the Treatment of HCV. Molecular Therapy, 2006, 13, S422-S423.	8.2	0
143	108. Study of an AAV-8 Capsid Mutant with Direct Heparin Binding Capability but Reduced Efficiency in Liver-Targeted Transduction. Molecular Therapy, 2006, 13, S44-S45.	8.2	0
144	11. Transposition from a Gene-Deleted Adenoviral Vector Results in Phenotypic Correction in a Canine Model for Hemophilia B. Molecular Therapy, 2006, 13, S5.	8.2	0

#	Article	IF	Citations
145	1066. A Novel Class of Miniature Stabilized Double-Stranded AAV (msdsAAV) Vectors for the In Vivo Expression of Short Hairpin RNAs. Molecular Therapy, 2006, 13, S409.	8.2	0
146	742. Molecular Evolution of Adeno-Associated Viral (AAV) Vectors Via DNA Family Shuffling of Primate and Non-Primate Serotypes. Molecular Therapy, 2006, 13, S287.	8.2	0
147	746. Localization of Structural Determinants in AAV Capsid for Efficient Liver Transduction by Domain Swapping between AAV-2 and AAV-8. Molecular Therapy, 2006, 13, S288.	8.2	0
148	489. Treatment for Hemophilia B Using Self- Complimentary AAV8 Vectors. Molecular Therapy, 2006, 13, S189-S190.	8.2	0
149	792. Post-Integrative Gene Silencing in the Sleeping Beauty Transposition System. Molecular Therapy, 2006, 13, S307.	8.2	0
150	1034. Expression of Short Hairpin RNAs by Liver and Non Liver Specific RNA Pol II Expression Cassettes: What Governs Activity?. Molecular Therapy, 2006, 13, S397.	8.2	0
151	680. Non-Viral Transposon Mediated Gene Transfer of Human Factor VIII to Hemophilia A Mice. Molecular Therapy, 2006, 13, S262.	8.2	0
152	805. Fatality in Mice Due to Oversaturation of Cellular Micro/Short Hairpin RNA Pathways. Molecular Therapy, 2006, 13, S312.	8.2	0
153	Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Molecular Therapy, 2006, 14, 45-53.	8.2	527
154	5. Mechanisms for Hairpin Loop Opening of â€œClosedâ€•AAV-ITRs by Specific Cellular Endonuclease Activities, a Prerequisite for rAAV Vector Genome Recombinations In Vivo. Molecular Therapy, 2006, 13, S2-S3.	8.2	0
155	539. Unraveling the Mechanisms Underlying Silencing/Activation of Episomal Vectors In Vivo. Molecular Therapy, 2006, 13, S207.	8.2	0
156	103. A Screen for Host Cellular Proteins That Interact with Adeno-Associated Virus Capsid Proteins Reveals Proteins Involved in AAV8 Transduction. Molecular Therapy, 2006, 13, S42-S43.	8.2	0
157	804. In Vivo Correction of a Metabolic Liver Disease by AAV8-Mediated Homologous Recombination. Molecular Therapy, 2006, 13, S311-S312.	8.2	0
158	Osteosarcoma Derived from Cultured Mesenchymal Stem Cells.. Blood, 2006, 108, 2554-2554.	1.4	21
159	Stability and Repeat Regeneration Potential of the Engineered Liver Tissues under the Kidney Capsule in Mice. Cell Transplantation, 2005, 14, 621-627.	2.5	36
160	Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology, 2005, 41, 132-140.	7.3	120
161	RNAi in drug development: Practical considerations. , 2005, , 384-395.		0
162	Large-Scale Molecular Characterization of Adeno-Associated Virus Vector Integration in Mouse Liver. Journal of Virology, 2005, 79, 3606-3614.	3.4	164

#	Article	IF	Citations
163	Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice. Journal of Virology, 2005, 79, 214-224.	3.4	299
164	Increased Maintenance and Persistence of Transgenes by Excision of Expression Cassettes from Plasmid SequencesIn Vivo. Human Gene Therapy, 2005, 16, 558-570.	2.7	48
165	Real-Time in Vivo Imaging of Stem Cells Following Transgenesis by Transposition. Molecular Therapy, 2005, 12, 42-48.	8.2	36
166	High-Resolution Genome-Wide Mapping of Transposon Integration in Mammals. Molecular and Cellular Biology, 2005, 25, 2085-2094.	2.3	298
167	Modified Infusion Procedures Affect Recombinant Adeno-Associated Virus Vector Type 2 Transduction in the Liver. Human Gene Therapy, 2005, 16, 299-306.	2.7	17
168	Improved Production and Purification of Minicircle DNA Vector Free of Plasmid Bacterial Sequences and Capable of Persistent Transgene ExpressionIn Vivo. Human Gene Therapy, 2005, 16, 126-131.	2.7	168
169	A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase Ï•C31 and the Sleeping Beauty transposase. Molecular Therapy, 2005, 11, 695-706.	8.2	75
170	Mesenchymal Cancer Cells Can Arise from Ex Vivo Modified Mesenchymal Stem Cells.. Blood, 2005, 106, 4326-4326.	1.4	0
171	In vivo activity of nuclease-resistant siRNAs. Rna, 2004, 10, 766-771.	3.5	483
172	Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectors. Journal of Virology, 2004, 78, 3110-3122.	3.4	333
173	Mutational Analysis of the N-Terminal DNA-Binding Domain of Sleeping Beauty Transposase: Critical Residues for DNA Binding and Hyperactivity in Mammalian Cells. Molecular and Cellular Biology, 2004, 24, 9239-9247.	2.3	142
174	Extracellular matrix component cotransplantation prolongs survival of heterotopically transplanted human hepatocytes in mice. Transplantation Proceedings, 2004, 36, 2469-2470.	0.6	7
175	Donor-Derived, Liver-Specific Protein Expression after Bone Marrow Transplantation. Transplantation, 2004, 78, 530-536.	1.0	7
176	Transgenesis of Multipotent Adult Progenitor Cells (MAPC) with Sleeping Beauty Transposons to Determine MAPC Homing and Persistence in Real-Time In Vivo.. Blood, 2004, 104, 2099-2099.	1.4	0
177	Real-Time In Vivo Biodistribution of Multipotent Adult Progenitor Cells (MAPC): Role of the Immune System in MAPC Resistance in Non-Transplanted and Bone Marrow Transplanted Mice.. Blood, 2004, 104, 507-507.	1.4	0
178	A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology, 2003, 38, 503-508.	7.3	78
179	Looking into the safety of AAV vectors. Nature, 2003, 424, 251-251.	27.8	58
180	AAV serotype 2 vectors preferentially integrate into active genes in mice. Nature Genetics, 2003, 34, 297-302.	21.4	359

#	Article	IF	Citations
181	Progress and problems with the use of viral vectors for gene therapy. Nature Reviews Genetics, 2003, 4, 346-358.	16.3	2,213
182	Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Molecular Therapy, 2003, 8, 495-500.	8.2	435
183	Optimization of Cis-Acting Elements for Gene Expression from Nonviral VectorsIn Vivo. Human Gene Therapy, 2003, 14, 215-225.	2.7	36
184	Inhibition of hepatitis B virus in mice by RNA interference. Nature Biotechnology, 2003, 21, 639-644.	17.5	595
185	Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Molecular Therapy, 2003, 7, 839-850.	8.2	311
186	Episomal Persistence of Recombinant Adenoviral Vector Genomes during the Cell Cycle In Vivo. Journal of Virology, 2003, 77, 7689-7695.	3.4	84
187	Pathways of Removal of Free DNA Vector Ends in Normal and DNA-PKcsâ€"Deficient SCID Mouse Hepatocytes Transduced with rAAV Vectors. Human Gene Therapy, 2003, 14, 871-881.	2.7	26
188	Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Molecular Therapy, 2003, 7, 101-111.	8.2	48
189	Helper-Independent sleeping beauty Transposonâ€"Transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Molecular Therapy, 2003, 8, 654-665.	8.2	138
190	Free DNA ends are essential for concatemerization of synthetic Double-Stranded Adeno-Associated virus vector genomes transfected into mouse hepatocytes in vivo. Molecular Therapy, 2003, 7, 112-121.	8.2	22
191	The effect of age on hepatic gene transfer with self-inactivating lentiviral vectors in vivo. Molecular Therapy, 2003, 8, 314-323.	8.2	42
192	Nonhomologous-End-Joining Factors Regulate DNA Repair Fidelity during Sleeping Beauty Element Transposition in Mammalian Cells. Molecular and Cellular Biology, 2003, 23, 8505-8518.	2.3	79
193	AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 2003, 101, 2963-2972.	1.4	707
194	A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood, 2003, 102, 2403-2411.	1.4	76
195	Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood, 2003, 102, 2412-2419.	1.4	196
196	Advancing Molecular Therapies through In Vivo Bioluminescent Imaging. Molecular Imaging, 2003, 2, 153535002003031.	1.4	6
197	In Vivo Correction of Murine Tyrosinemia Type I by DNA-Mediated Transposition. Molecular Therapy, 2002, 6, 759-769.	8.2	137
198	Determinants of Hepatitis C Translational Initiation in Vitro, in Cultured Cells and Mice. Molecular Therapy, 2002, 5, 676-684.	8.2	85

#	Article	IF	Citations
199	A Limited Number of Transducible Hepatocytes Restricts a Wide-Range Linear Vector Dose Response in Recombinant Adeno-Associated Virus-Mediated Liver Transduction. Journal of Virology, 2002, 76, 11343-11349.	3.4	92
200	A new adenoviral helperâ€"dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood, 2002, 99, 3923-3930.	1.4	133
201	Role of Hepatocyte Direct Hyperplasia in Lentivirus-Mediated Liver TransductionIn Vivo. Human Gene Therapy, 2002, 13, 653-663.	2.7	49
202	Gene transfer for hemophilia and viral infection. International Journal of Hematology, 2002, 76, 147-147.	1.6	1
203	RNA Interference Gene Therapy: A story of mice and men. Gene Therapy, 2002, 9, 1563-1563.	4.5	11
204	RNA interference in adult mice. Nature, 2002, 418, 38-39.	27.8	1,043
205	Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nature Biotechnology, 2002, 20, 999-1005.	17.5	184
206	Modified HIV-1 Based Lentiviral Vectors Have an Effect on Viral Transduction Efficiency and Gene Expression in Vitro and in Vivo. Molecular Therapy, 2001, 4, 164-173.	8.2	98
207	Hepatocyte transplantation: clinical and experimental application. Journal of Molecular Medicine, 2001, 79, 617-630.	3.9	122
208	Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature Medicine, 2001, 7, 33-40.	30.7	1,205
209	Linear DNAs Concatemerize in Vivo and Result in Sustained Transgene Expression in Mouse Liver. Molecular Therapy, 2001, 3, 403-410.	8.2	179
210	Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in Males. Molecular Therapy, 2001, 4, 586-592.	8.2	152
211	Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo. Journal of Virology, 2001, 75, 6969-6976.	3.4	417
212	Efficient lentiviral transduction of liver requires cell cycling in vivo. Nature Genetics, 2000, 24, 49-52.	21.4	278
213	Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nature Medicine, 2000, 6, 327-331.	30.7	172
214	Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genetics, 2000, 24, 257-261.	21.4	971
215	Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nature Biotechnology, 2000, 18, 527-532.	17.5	191
216	Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nature Genetics, 2000, 25, 35-41.	21.4	491

#	Article	IF	Citations
217	Therapeutic levels of human factor VIII and IX using HIV-1â€"based lentiviral vectors in mouse liver. Blood, 2000, 96, 1173-1176.	1.4	144
218	Nonrandom Transduction of Recombinant Adeno-Associated Virus Vectors in Mouse Hepatocytes In Vivo: Cell Cycling Does Not Influence Hepatocyte Transduction. Journal of Virology, 2000, 74, 3793-3803.	3.4	124
219	Inclusion of the Hepatic Locus Control Region, an Intron, and Untranslated Region Increases and Stabilizes Hepatic Factor IX Gene Expression in Vivo but Not in Vitro. Molecular Therapy, 2000, 1, 522-532.	8.2	230
220	Recruitment of Single-Stranded Recombinant Adeno-Associated Virus Vector Genomes and Intermolecular Recombination Are Responsible for Stable Transduction of Liver In Vivo. Journal of Virology, 2000, 74, 9451-9463.	3.4	174
221	Isolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver. Journal of Virology, 1999, 73, 5438-5447.	3.4	178
222	Integrating Adenovirusâ€"Adeno-Associated Virus Hybrid Vectors Devoid of All Viral Genes. Journal of Virology, 1999, 73, 9314-9324.	3.4	92
223	Adeno-Associated Virus Vectors and Hematology. Blood, 1999, 94, 864-874.	1.4	97
224	Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Medicine, 1999, 5, 64-70.	30.7	414
225	Implication of Interfering Antibody Formation and Apoptosis as Two Different Mechanisms Leading to Variable Duration of Adenovirus-Mediated Transgene Expression in Immune-Competent Mice. Journal of Virology, 1999, 73, 4755-4766.	3.4	32
226	IMAGe, a New Clinical Association of Intrauterine Growth Retardation, Metaphyseal Dysplasia, Adrenal Hypoplasia Congenita, and Genital Anomalies. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4335-4340.	3.6	26
227	The kinetics of rAAV integration in the liver. Nature Genetics, 1998, 19, 13-15.	21.4	181
228	Hepatocyte growth factor induces hepatocyte proliferationin vivo and allows for efficient retroviral-mediated gene transfer in mice. Hepatology, 1998, 28, 707-716.	7.3	112
229	Efficient Construction of a Recombinant Adenovirus Vector by an ImprovedIn VitroLigation Method. Human Gene Therapy, 1998, 9, 2577-2583.	2.7	329
230	Methods for Delivery of Genes to Hepatocytes In Vivo Using Recombinant Adenovirus Vectors. , 1997, 7, 205-212.		1
231	Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nature Biotechnology, 1997, 15, 1383-1387.	17.5	43
232	Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genetics, 1997, 16, 270-276.	21.4	589
233	Method for Multiple Portal Vein Infusions in Mice: Quantitation of Adenovirus-Mediated Hepatic Gene Transfer. BioTechniques, 1996, 20, 278-285.	1.8	104
234	Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology, 1995, 21, 815-819.	7.3	94

#	Article	IF	Citations
235	Longâ€“term hepatic adenovirusâ€“mediated gene expression in mice following CTLA4Ig administration. Nature Genetics, 1995, 11, 191-197.	21.4	298
236	A Modified Urokinase Plasminogen Activator Induces Liver Regeneration Without Bleeding. Human Gene Therapy, 1995, 6, 1029-1037.	2.7	49
237	Assessment of Recombinant Adenoviral Vectors for Hepatic Gene Therapy. Human Gene Therapy, 1993, 4, 403-409.	2.7	327
238	Development of a Clinical Protocol for Hepatic Gene Transfer: Lessons Learned in Preclinical Studies. Pediatric Research, 1993, 33, 313-320.	2.3	12
239	In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science, 1993, 262, 117-119.	12.6	315
240	Hepatic Gene Therapy: Persistent Expression of Human Î±1-Antitrypsin in Mice after Direct Gene Delivery In Vivo. Human Gene Therapy, 1992, 3, 641-647.	2.7	182
241	Escherichia coli Sepsis and Prolonged Hypophosphatemia Following Exertional Heat Stroke. Pediatrics, 1990, 86, 307-309.	2.1	4